title: Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis.
abstract: To study the feature and prognostic contribution of cytogenetic information in Chinese patients with primary myelofibrosis (PMF), we analyzed cytogenetic data from 565 patients with PMF. One hundred and sixty-two subjects (29%) had abnormal karyotypes, including trisomy 8 (45; 28%), deletion of 20q (25; 15%), deletion of 13q (13; 8%), deletion of 11q (12; 7%), and abnormal chromosome 1 (21; 13%); balanced translocations (14; 9%); a complex karyotype (CK; 30; 19%), and a monosomal karyotype (MK; 19; 12%). Using these data, we showed that the Dynamic International Prognostic Scoring System (DIPSS)-plus, which includes cytogenetic information, is a better survival predictor than the DIPSS. We next used our data to construct the following two cytogenetic-based cohorts: (1) favorable karyotype-subjects with a normal karyotype, a CK that is not a MK, +8 only or a balanced translocation only and (2) unfavorable karyotype-all others. The median survival times were not reached and were 52 month (95% CI, 32-72 months; P = 0.01) in patients with favorable and unfavorable karyotypes, respectively. These data provided the detailed cytogenetic information in Chinese patients with PMF and confirmed the impact of cytogenetic abnormalities on survival in Chinese patients.
authors.affiliation: MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
authors.forename: Bing
authors.initials: B
authors.lastname: Li
authors.forename: Junqing
authors.initials: J
authors.lastname: Xu
authors.forename: Chengwen
authors.initials: C
authors.lastname: Li
authors.forename: Robert Peter
authors.initials: RP
authors.lastname: Gale
authors.forename: Zefeng
authors.initials: Z
authors.lastname: Xu
authors.forename: Tiejun
authors.initials: T
authors.lastname: Qin
authors.forename: Yue
authors.initials: Y
authors.lastname: Zhang
authors.forename: Gang
authors.initials: G
authors.lastname: Huang
authors.forename: Liwei
authors.initials: L
authors.lastname: Fang
authors.forename: Hongli
authors.initials: H
authors.lastname: Zhang
authors.forename: Lijuan
authors.initials: L
authors.lastname: Pan
authors.forename: Naibo
authors.initials: N
authors.lastname: Hu
authors.forename: Shiqiang
authors.initials: S
authors.lastname: Qu
authors.forename: Zhijian
authors.initials: Z
authors.lastname: Xiao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D044466:Asian People / Q000235:genetics*; D001772:Blood Cell Count; D002648:Child; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D059785:Karyotype; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating; D011237:Predictive Value of Tests; D055728:Primary Myelofibrosis / Q000097:blood / Q000208:ethnology / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D012720:Severity of Illness Index; D016037:Single-Blind Method; D013163:Splenomegaly / Q000209:etiology; D016019:Survival Analysis; D014178:Translocation, Genetic; D014314:Trisomy; D055815:Young Adult